大剂量沐舒坦治疗慢性阻塞性肺病急性加重期的临床研究  

Clinical study of high-dose ambroxol for treatment of acute exacerbations in chronic obstructive pulmonary disease

作　　者：李勇[1] 吴峰[1] 林挺岩[1] 

机构地区：[1]福建医科大学附属协和医院呼吸内科,福州350000

出　　处：《中华老年医学杂志》2013年第2期162-164,共3页Chinese Journal of Geriatrics

摘　　要：目的评价大剂量沐舒坦静脉注射在治疗慢性阻塞性肺病急性加重期（AECOPD）的临床疗效。方法选择126例AECOPD患者，按随机对照原则分为三组：对照组40例，仅给予抗生素治疗、吸氧及支气管扩张剂等治疗；常规剂量沐舒坦组（常规剂量组）40例，给予沐舒坦30mg，3次／d静脉滴注治疗7d，其余治疗与对照组相同；大剂量沐舒坦组（大剂量组）46例，给予沐舒坦150mg，2次／d治疗7d，其余治疗与对照组相同。结果大剂量组和常规剂量组治疗总有效率分别为95.6％、77.5％，均显著高于对照组55．0％（x2=19．阻、4．53，均P〈0．05）。大剂量组和常规剂量组平均住院日分别为（10．78±0．95）d，（11．75±0．84）d，均显著低于对照组（13．15±0．89）d（q=1l·88、7·24，均P〈0．05），且大剂量组临床疗效更好。结论大剂量沐舒坦治疗AECOPD患者疗效显著。目安全性好。Objective To evaluate the etticacy and salety oi hlgn-ctose amoroxoi in treaung acute exacerbations in chronic obstructive pulmonary disease （AECOPD）. Methods The trial design was random, open, and parallel control. 126 patients with AECOPD were involved. High-dose group received ambroxol 150 mg 3 times per day for 7 days （n= 46）, while conventional-dose group given amhroxol 30 mg 3 times per day for 7 days （n=40） and control group was given a routine treatment （antibiotic therapy, oxygen inhalation and bronchodilators） （n= 40）. Results The effective rates of high-dose group and conventional dose group （95.6 ~, 77.5 ~） were significantly higher compared with control group （55.0~） （Z2 19.81, 4.53, both P〈0.05）. The average duration of hospitalization was significantly lower in high-dose group （10.78 ± 0.95）d and conventional-dose group （11.75±0.84）d comparing with control group （13.15±0.89）d （q= 11.88, 7.24, both P〈0.05）. The clinical efficacy in high dose group was much better. Conclusions High dose ambroxol is a safe and efficient therapy in the treatment of acute exacerbations in chronic obstructive pulmonary disease.

关 键 词：沐舒坦 慢性阻塞性肺病急性加重期 静脉滴注 

分 类 号：R563.9[医药卫生—呼吸系统]